Abstract
The noradrenergic system shows pathological modifications in aging and neurodegenerative diseases and is thought to be affected in the early stages of both Alzheimer and Parkinson’ ss diseases. We conducted a meta-analysis of noradrenergic differences in Alzheimer’s disease type dementia (ADD) and Parkinson’s disease (PD) using CSF and PET biomarkers. CSF noradrenaline (NA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) as well as NA transporter availability (PET MeNER) levels in controls, ADD and PD patients was summarized from 26 articles (1025 patients and 839 controls in total) using a random-effects model meta-analysis. Compared with controls, PD patients showed significant reductions in CSF NA and MHPG, and PET MeNER binding in the hypothalamus. In ADD, MHPG levels were increased compared with controls. Age correlated with CSF MHPG levels in ADD, but not in PD. Noradrenergic dysfunction in neurodegenerative diseases can be detected using CSF or PET measures and may be more pronounced in PD compared to ADD.
Competing Interest Statement
H.Z. has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, from which he received payments, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work), position for which he receives financial support, and is chair of the Alzheimer's Association Global Biomarker Standardization Consortium and the Alzheimer's Association Biofluid-Based Biomarker Professional Interest Area, free of charge. E.D. has received payments for his role and work as consultant for Roche, Biogen, RoxHealth and expert testimony for UCL Consultancy, served at scientific advisory boards for EdoN Initiative and Ebsen Alzheimers Center (no payment) and for Roche (personal financial support), and is a co-founder of the digital health start-up Neotiv. E.L., L.H., F.B., M.R., N.J.A. and M.B. have nothing to disclose.
Funding Statement
None of the authors received financial support for the specific purpose of writing this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used for this meta-analysis are partly openly accessible by consulting the articles from which they were extracted, and partly sent by the authors after our specific request. The codes used to conduct the meta-analysis are available on the GitHub page of the corresponding author.
